Drug-related side effects after rituximab infusion in patients with chronic lymphocytic leukemia

Drug-related side effects after rituximab infusion in patients with chronic lymphocytic leukemia

Authors

  • Giovanni D'Arena Hematology and Stem Cell Transplantation Unit IRCCS Centro di Riferimento Oncologico della Basilicata Rionero in Vulture (PZ)
  • Sonya De Lorenzo Hematology Unit, “Tortora” Hospital, Pagani (SA),
  • Maria Luigia Vigliotti Hematology Unit, “San Sebastiano” Hospital, Caserta, Italy
  • Idanna Innocenti Hematology Unit, Catholic University of “Sacred Hearth”, Rome, Italy
  • Michele Cimminiello Hematology Unit, “San Carlo” Hospital, Potenza, Italy;
  • Vittorio Simeon Laboratory of Preclinical and Translational Research, IRCCS Referral Cancer Center of Basilicata, Rionero in Vulture (PZ);
  • Francesco Autore Hematology Unit, Catholic University of “Sacred Hearth”, Rome, Italy
  • Giuliana Farina Hematology Unit, “San Sebastiano” Hospital, Caserta, Italy
  • Vincenzo Patella Allergology Unit, “Santa Maria della Speranza” Hospital, Battipaglia (SA);
  • Vincenzo De Feo Department of Pharmacology, University of Salerno, Italy
  • Pellegrino Musto Scientific Direction, IRCCS Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), Italy
  • Luca Laurenti Hematology Unit, Catholic University of “Sacred Hearth”, Rome, Italy;

Keywords:

rituximab, chronic lymphocytic leukemia, infusional adverse events

Abstract

A great advance in the treatment of all CD20 positive B-cell lymphoproliferative disorders has been achieved by the addition of anti-CD20 monoclonal antibody Rituximab to standard chemotherapy. As a consequence, Rituximab has also greatly expanded the treatment options for patients with chronic lymphocytic leukemia (CLL), a “mature” B-cell malignancy characterized by an increase in marrow and circulating neoplastic B-lymphocytes. Interestingly, several autoimmune disorders are also successfully treated with Rituximab.

[...]

Author Biography

Giovanni D'Arena, Hematology and Stem Cell Transplantation Unit IRCCS Centro di Riferimento Oncologico della Basilicata Rionero in Vulture (PZ)

Direttore incaricato

U.O. di Ematologia e Trapianto di cellule staminali

Downloads

Published

2015-09-21

Issue

European Journal of Oncology Vol.20, No 1 (2015)

Section

Letters to the Editor

License

OPEN ACCESS

All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.

The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).

Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.

How to Cite

1.
D'Arena G, De Lorenzo S, Vigliotti ML, Innocenti I, Cimminiello M, Simeon V, et al. Drug-related side effects after rituximab infusion in patients with chronic lymphocytic leukemia. Eur J Oncol Env Hea [Internet]. 2015 Sep. 21 [cited 2025 Apr. 6];20(1):64-7. Available from: https://mattioli1885journals.com/index.php/EJOEH/article/view/4249